Clinical Trials

166 studies in Hematology

  1. Neuroblastoma Biology Studies
    1. Minnesota
  2. Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
    1. Minnesota
  3. Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
    1. Minnesota
  4. Familial Barrett's Esophagus
    1. Minnesota
  5. A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction
    1. Minnesota
  6. A Pilot Study of Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer
    1. Minnesota
  7. Randomized Phase II Study of AB (Abraxane™, Bevacizumab) Versus Ipilimumab for 1st Line Therapy of Unresectable Stage IV Metastatic Malignant Melanoma (BRAF V600E Negative)
    1. Minnesota
  8. A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma
    1. Minnesota
  9. A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
    1. Florida,
    2. Minnesota
  10. A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
    1. Arizona,
    2. Florida
  1. Prev
  2. 5
  3. 6
  4. 7
  5. 8
  6. 9
  7. Next

Clinical Trials

166 studies in Hematology

  1. Neuroblastoma Biology Studies
    1. Minnesota
  2. Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
    1. Minnesota
  3. Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
    1. Minnesota
  4. Familial Barrett's Esophagus
    1. Minnesota
  5. A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction
    1. Minnesota
  6. A Pilot Study of Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer
    1. Minnesota
  7. Randomized Phase II Study of AB (Abraxane™, Bevacizumab) Versus Ipilimumab for 1st Line Therapy of Unresectable Stage IV Metastatic Malignant Melanoma (BRAF V600E Negative)
    1. Minnesota
  8. A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma
    1. Minnesota
  9. A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
    1. Florida,
    2. Minnesota
  10. A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
    1. Arizona,
    2. Florida
  1. Prev
  2. 5
  3. 6
  4. 7
  5. 8
  6. 9
  7. Next
.

Mayo Clinic Footer